The aim of this study is to evaluate the effectiveness of allopurinol treatment at 12 months on the adaptive and cognitive functioning of patients with adenylosuccinate lyase deficiency (ADSL). The psychiatric evaluation will involve the use of standardized tools prior to initiation of treatment, and will be repeated 6 months and 12 months after the start of treatment. The decrease in the concentration of SAICAR and S-Ado metabolites, which are markers of adenylosuccinate lyase (ADSL) deficiency, will also be quantified. Similarly, the efficacy of allopurinol on epileptic seizures for epileptic patients and on electrocardiogram abnormalities will be evaluated secondarily
Adenylosuccinate lyase deficiency (ADSL) is a rare disorder of purine metabolism whose symptoms are mental retardation, autistic disorders, epilepsy, related to the accumulation of succinylpurines: succinylaminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S- Ado). The S-Ado / SAICAr ratio in the cerebrospinal fluid (CSF) is correlated with the clinical severity: the cerebral toxicity of SAICAr is incriminated. There is no specific treatment. Based on the work of Gertrude B. Elion (1988 Nobel Prize in Medicine), who reports that allopurinol (a structural analogue of hypoxanthine) can be a substrate for hypoxanthine phosphoribosyltransferase (HPRT) and thus produce allopurinol ribonucleotides with as a first step in the de novo synthesis of purines, investigators tested the hypothesis that treatment with allopurinol in children with ADSL deficiency would reduce the production of the toxic metabolite SAICAr. This hypothesis was validated in 3 minor patients with biological and clinical improvement. So the investigators put the phase II, non-comparative study based on 4 visits to Necker-Enfants malades Hospital or La Pitié-Salpêtrière Hospital: Month 0 (before treatment), Month 3, Month 6 and Month 12 after the start of treatment. After verification of the inclusion criteria and information of the parents or the patient or guardian, signature of the consent and inclusion of the patient: * Clinical and neurological evaluation; * Psychiatric assessment with standardized tests; * Biological evaluation: determination of urinary and plasma metabolites (SAICAr, S-Ado, ...) Experimental treatment: Allopurinol (Zyloric®) will be administered orally for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Daily oral administration
LA PITIE-SALPETRIERE Hospital, AP-HP
Paris, France
Department of Pediatry. Reference centre of Hereditary diseases of the metabolism of child and adult. Necker - Enfants malades Hospital
Paris, France
Measurement of adaptive functional improvement : composite total score for Vineland II adaptive behaviour Scale
to assess Efficacy of Allopurinol (Zyloric)® treatment from Baseline : For each scale : Mean : 100 SD : 15 * Adaptive behaviour composite : Range 20 to 180 -Domains scores : Range 20 to 140 -Communication : Range 20 to 140 -Daily living skills : Range 20 to 140 -Socialization : 20 to 140 -Motor skills : 20 to 140 For each scale values are considered to be better or worse outcome :High 130 to 140 -Moderately High 115 to 129 -Adequate 86 to 114 -Moderately Low 71 to 85 -Low 20 to 70 Total score is obtained by summing the subdomains scores
Time frame: 12 months
Evolution of the Scores of different subdomains Vineland II scale from baseline
Clinical evolution for developmental and cognitive assessment
Time frame: at 0, 6 months and 12 months
Evolution of the Psycho-Educative Profile (PEP III/R) from baseline
Clinical evolution for developmental and cognitive assessment
Time frame: at 0, 12 months
Evolution of the Score ADI-R (Autism Diagnostic Interview-Revised) from baseline
Clinical evaluation for autistic symptoms : scale ranges : * A : Social interactions: 0 to 30 (significative if \>10) * B : Communication : 0 to 26 (significative if \> 7 or 8) * C : Repetitive and restricted interests : 0 to 16 (significative if \>3) * D : Developmental abnormality present before 36 months : 0 to 5 (significative if \>1) better score : 0 (non autistic) - worse score : the higher score is the worst
Time frame: at 0, 12 months
Evolution of the Score ADOS-2 (Autism Diagnostic Observation Schedule 2) from baseline
Clinical evaluation for autistic symptoms. Scale ranges : * A : Socialization : social interactions and communication : 0 to 20 (social interactions : 0 to 6 -communication : 0 to 14) * B : Restricted and repetitive interests : 0 to 8 * Total : A+B : 0 to 28 Autism : total score\>12 - Autism Spectrum Disorder : total score \>8 Better score : 0 - Worse score : the highest score is the worst
Time frame: at 0, 12 months
Evolution of the Score on Conners hyperactivity Scale
Clinical evolution for behavioral disorders and adaptive functioning Conners Scale for Parents : \- Subscales : Behavioural difficulties (items 2-8-14-19-20-27-35-39) : 0 to 24 Learning difficulties (items 10-25-31-37) : 0 to 12 Somatisation (items 32-41-43-44) : 0 to 12 Impulsivity, hyperactivity (items 4-5-11-13): 0 to 12 Anxiety (items 12-16-24-47): 0 to 12 -Hyperactivity index : sum of the items (4-7-11-13-14-25-31-33-37-38) divided by 10 : 0 to 3 Conners Scale for teachers : \- Subscales : Behavioural difficulties (items 4-5-6-10-11-12-23-27) : 0 to 24 Impulsivity, hyperactivity (items 1-2-3-8-14-15-16) : 0 to 21 Inattention, passivity (items 7-9-18-20-21-22-26-28) : 0 to 24 -Hyperactivity index (sum of the items 1-5-7-8-10-11-14-15-21-26 divided by 10) : 0 to 3 Better score : 0 - Worse score : the highest score is the worst -Hyperactivity index : Significative if\> 1,5
Time frame: at 0, 6 months and 12 months
Evolution of the Score on ABC scale (Aberrant Behaviour Checklist)
Clinical evolution for behavioral disorders and adaptive functioning scale ranges : * Irritability : 0 to 45 * Lethargy : 0 to 48 * Stereotypy : 0 to 21 * Hyperactivity : 0 to 48 * Inappropriate speech : 0 to 12 Better score : 0 -Worse score : the highest score is the worst on each scale- there is no total score
Time frame: at 0, 6 months and 12 months
Evolution of SAICAr levels in the urine
Evolution of the quantity of urinary metabolites from Baseline
Time frame: at 0, 6 months and 12 months
Evolution of S-Ado levels in the urine
Evolution of the quantity of urinary metabolites from Baseline
Time frame: at 0, 6 months and 12 months
Evolution of SAICAr levels in the blood
Evolution of the quantity of plasma metabolites from Baseline
Time frame: at 0, 6 months and 12 months
Evolution of S-Ado levels in the blood
Evolution of the quantity of plasma metabolites from Baseline
Time frame: at 0, 6 months and 12 months
Evolution of the number of seizures from Baseline for epileptic patients
at baseline, performing neurological examinations and interrogation
Time frame: at 0 and 12 months
Evolution of antiepileptic treatments from Baseline for epileptic patients
at baseline, performing neurological examinations and interrogation
Time frame: at 0 and 12 months
Evolution of electroencephalogram tracing from Baseline for epileptic patients
normal/abnormal
Time frame: at 0 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.